Displaying drugs 376 - 400 of 8039 in total
Rilpivirine
Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance...
Approved
Matched Description: … [A31329] The internal conformational flexibility of rilpivirine and the plasticity of it interacting ... Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of ... binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's …
Matched Categories: … Antivirals used in combination for the treatment of HIV infections …
Matched Categories: … Antivirals used in combination for the treatment of HIV infections …
Dabigatran etexilate
Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor dabigatran.[A177463, A6970, L34675, L34680] Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated. In contrast to warfarin, because its anticoagulant effects...
Approved
Matched Description: … [A177463, A6970, L34675, L34680] Dabigatran etexilate may be used to decrease the risk of venous thromboembolic …
Silodosin
Silodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α1A subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the α1A subtype accounts for approximately 75% of α1-adrenoceptors in the prostate. Silodosin was first approved by...
Approved
Matched Description: … a negative impact on the quality of life of patients. ... It is indicated for the symptomatic treatment of benign prostatic hyperplasia in adults. ... Silodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α1A
Irinotecan
Irinotecan is a topoisomerase inhibitor used for chemotherapy. It is a water-soluble analogue of camptothecin, which is extracted from the Chinese tree Camptotheca acuminate. The bis-piperidine side chain in the structure of irinotecan bestows enhanced water solubility. As an anticancer drug, irinotecan was first commercially available in Japan in 1994...
Approved
Investigational
Matched Description: … [L50186]
The active metabolite SN-38 is also a potent inhibitor of DNA topoisomerase I. ... This leads to the arrest of the cell cycle in the S-G2 phase and cancer cell death.[A263376] ... It is a water-soluble analogue of [camptothecin], which is extracted from the Chinese tree _Camptotheca …
Biperiden
A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.
Approved
Investigational
Matched Description: … It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. …
Ritlecitinib
Ritlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family. In June 2023, it was approved by the FDA for the treatment of severe alopecia areata in adults and adolescents 12 years and older.[L47092,L47127] It was further...
Approved
Investigational
Matched Description: … of alopecia areata. ... [L48181] Ritlecitinib is administered orally and is the first member of its class. ... Ritlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine …
Levothyroxine
Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quantities of the...
Approved
Matched Description: … of ~1:4 (T4:T3). ... Without sufficient quantities of circulating thyroid hormones, symptoms of hypothyroidism begin to develop ... This higher proportion of T3 in desiccated thyroid products can lead to supraphysiologic levels of T3 …
Lefamulin
Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019. This drug is...
Approved
Investigational
Matched Description: … some of its antimicrobial activity. ... Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia ... A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus …
Tyrosine
Tyrosine is a non-essential amino acid. In animals it is synthesized from phenylalanine. It is also the precursor of epinephrine, thyroid hormones, and melanin.
Approved
Investigational
Nutraceutical
Matched Description: … It is also the precursor of [epinephrine], thyroid hormones, and melanin. …
Eltrombopag
Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of...
Approved
Matched Description: … Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood ... ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets …
Elexacaftor
Elexacaftor (previously VX-445) is a small molecule, next-generation corrector of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. It received FDA approval in October 2019 in combination with tezacaftor and ivacaftor as the combination product TrikaftaTM. Elexacaftor is considered a next-generation CFTR corrector as it possesses both a different structure...
Approved
Investigational
Matched Description: … Elexacaftor (previously VX-445) is a small molecule, next-generation corrector of the cystic fibrosis ... [A187361] While dual corrector/potentiator combination therapy has proven useful in the treatment of ... a subset of CF patients,[A187358] their use is typically limited to patients who are homozygous for the …
Moxifloxacin
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
Approved
Investigational
Leucovorin
Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro, the...
Approved
Matched Description: … Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary ... of osteosarcoma or for diminishing the toxicity associated with inadvertent overdosage of folic acid ... This results in a deficiency of coenzymes and a resultant buildup of toxic substances that are responsible …
Orlistat
The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical intervention is required. Orlistat is a...
Approved
Investigational
Matched Description: … life and increasing the cost of healthcare. ... The global prevalence of obesity is increasing rapidly. ... Obesity-related complications lead to significant personal and economic burden by reducing quality of …
Tafenoquine
Tafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group.[A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria. Tafenoquine was...
Approved
Investigational
Matched Description: … Tafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy ... [A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in …
Cabazitaxel
Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to...
Approved
Filgotinib
Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases.[A221451,A221456] The disease is associated with extra-articular manifestations, progressive disability, and comorbidities including cardiovascular disease and mental disorders. 50-70% of patients with RA are unable to...
Approved
Investigational
Matched Description: … autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of ... of several treatments including disease-modifying anti-rheumatic drugs (DMARDS) like [methotrexate], ... immune and hematologic functions; therefore, selectivity for JAK1 aims to improve the safety profile of …
Atenolol
Atenolol is a cardioselective beta-blocker used in a variety of cardiovascular conditions.
Sir James Black, a Scottish pharmacologist, pioneered the use of beta-blockers for the management of angina pectoris in 1958 for which he received the Nobel Prize. Beta-blockers quickly became popular in clinical use and where subsequently investigated for...
Approved
Matched Description: … Sir James Black, a Scottish pharmacologist, pioneered the use of beta-blockers for the management of ... shows a risk ratio of 0.88 for cardiovascular disease risk and a risk ratio of 0.99 for mortality. ... [A235860,A235865] A meta-analysis of over 145,000 patients showed the risk of stroke in patients taking …
Metyrosine
An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed)
Approved
Matched Description: … An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines ... It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma …
Magnesium silicate
Magnesium silicate is a compound of magnesium oxide and silicon. It is the magnesium salt of silicic acid containing an unspecified amount of water. The molecular formula can be expressed more clearly as MgSiO3.xH2O. It is known as talc and it presents many uses in the cosmetic industry, food industry...
Approved
Matched Description: … It is the magnesium salt of silicic acid containing an unspecified amount of water. ... Magnesium silicate is a compound of magnesium oxide and silicon. ... [L2603] Under the FDA, magnesium silicate is determined as a member of the substances generally recognized …
Eribulin
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of...
Approved
Investigational
Matched Description: … Eribulin is also being investigated for use in the treatment of advanced solid tumors [A7439]. ... Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer ... who have previously received at least two chemotherapeutic regimens for the treatment of metastatic …
Trastuzumab emtansine
Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis....
Approved
Investigational
Matched Description: … formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of ... T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent ... Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal …
Deutetrabenazine
Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated DB04844 . The presence of deuterium in deutetrabenazine increases the half-lives of the active metabolite and prolongs their pharmacological activity...
Approved
Investigational
Matched Description: … In clinical trials of patients with HD, 12 weeks of treatment of deutetrabenazine resulted in overall ... the motor symptoms of HD and is not proposed to halt the progression of the disease [T28]. ... The presence of deuterium in deutetrabenazine increases the half-lives of the active metabolite and prolongs …
Ivacaftor
Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012 , and by Health Canada in late 2012. Ivacaftor is administered...
Approved
Matched Description: … the control of infections, nutritional support, clearance of mucus, and management of symptoms rather ... CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, ... [A20302]
Prior to the development of ivacaftor, management of CF primarily involved therapies for …
Fosnetupitant
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form...
Approved
Matched Description: … impact on the quality of life of patients receiving certain antineoplastic therapies [A32865]. ... Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality ... Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense …
Displaying drugs 376 - 400 of 8039 in total